Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00323947 · ClinicalTrials.gov registry record · Phase 4
Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy
A Phase 4 study, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 33
- Enrollment target
NCT00323947 is a Phase 4 study that has completed, run by Boston Children's Hospital. The registered enrollment target is 33 participants.
The verdict
NCT00323947, a Phase 4 study, has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 33 participants
- Enrollment target
Study Summary
This study will evaluate the safety and effectiveness of extended release methylphenidate (XR-MPH) in treating attention deficit hyperactivity disorder (ADHD) in children with both ADHD and epilepsy.
Interventions
- DRUG Extended Release Methylphenidate (OROS-Methylphenidate)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2003-05 |
| Est. Completion | 2007-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00323947
The ClinicalTrials.gov registry entry for NCT00323947 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Extended Release Methylphenidate (OROS-Methylphenidate) is the first listed.
NCT00323947 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00323947 about?
NCT00323947 is a clinical study titled "Methylphenidate for Treating Attention Deficit Hyperactivity Disorder in Children With Both ADHD and Epilepsy". This study will evaluate the safety and effectiveness of extended release methylphenidate (XR-MPH) in treating attention deficit hyperactivity disorder (ADHD) in children with both ADHD and epilepsy.
What is the current status of trial NCT00323947?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 33 participants. The study started on 2003-05. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00323947?
The interventions under investigation include: Extended Release Methylphenidate (OROS-Methylphenidate) (DRUG).
Who is sponsoring clinical trial NCT00323947?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.